Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Treated With Ocrelizumab.
Vukusic S, Bove R, Dobson R, McElrath T, Oreja-Guevara C, Pietrasanta C, Lin CJ, Ferreira G, Craveiro L, Zecevic D, Pasquarelli N, Hellwig K. Vukusic S, et al. Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200349. doi: 10.1212/NXI.0000000000200349. Epub 2024 Dec 17. Neurol Neuroimmunol Neuroinflamm. 2025. PMID: 39689270 Free PMC article.
Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants.
Bove R, Hellwig K, Pasquarelli N, Borriello F, Dobson R, Oreja-Guevara C, Lin CJ, Zecevic D, Craveiro L, McElrath T, Vukusic S. Bove R, et al. Among authors: vukusic s. Mult Scler Relat Disord. 2022 Aug;64:103963. doi: 10.1016/j.msard.2022.103963. Epub 2022 Jun 11. Mult Scler Relat Disord. 2022. PMID: 35753176 Free article.
Women's Health in Multiple Sclerosis: A Scoping Review.
Ross L, Ng HS, O'Mahony J, Amato MP, Cohen JA, Harnegie MP, Hellwig K, Tintore M, Vukusic S, Marrie RA. Ross L, et al. Among authors: vukusic s. Front Neurol. 2022 Jan 31;12:812147. doi: 10.3389/fneur.2021.812147. eCollection 2021. Front Neurol. 2022. PMID: 35173669 Free PMC article.
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
Tur C, Dubessy AL, Otero-Romero S, Amato MP, Derfuss T, Di Pauli F, Iacobaeus E, Mycko M, Abboud H, Achiron A, Bellinvia A, Boyko A, Casanova JL, Clifford D, Dobson R, Farez MF, Filippi M, Fitzgerald KC, Fonderico M, Gouider R, Hacohen Y, Hellwig K, Hemmer B, Kappos L, Ladeira F, Lebrun-Frénay C, Louapre C, Magyari M, Mehling M, Oreja-Guevara C, Pandit L, Papeix C, Piehl F, Portaccio E, Ruiz-Camps I, Selmaj K, Simpson-Yap S, Siva A, Sorensen PS, Sormani MP, Trojano M, Vaknin-Dembinsky A, Vukusic S, Weinshenker B, Wiendl H, Winkelmann A, Zuluaga Rodas MI, Tintoré M, Stankoff B. Tur C, et al. Among authors: vukusic s. Mult Scler. 2022 Aug;28(9):1424-1456. doi: 10.1177/13524585211069068. Epub 2022 Feb 23. Mult Scler. 2022. PMID: 35196927 Review.
Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
Vukusic S, Brassat D, de Seze J, Izquierdo G, Lysandropoulos A, Moll W, Vanopdenbosch L, Arque MJ, Kertous M, Rufi P, Oreja-Guevara C. Vukusic S, et al. Mult Scler Relat Disord. 2019 Apr;29:7-14. doi: 10.1016/j.msard.2019.01.019. Epub 2019 Jan 6. Mult Scler Relat Disord. 2019. PMID: 30654246 Clinical Trial.
Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
Roos I, Leray E, Frascoli F, Casey R, Brown JWL, Horakova D, Havrdova EK, Trojano M, Patti F, Izquierdo G, Eichau S, Onofrj M, Lugaresi A, Prat A, Girard M, Grammond P, Sola P, Ferraro D, Ozakbas S, Bergamaschi R, Sá MJ, Cartechini E, Boz C, Granella F, Hupperts R, Terzi M, Lechner-Scott J, Spitaleri D, Van Pesch V, Soysal A, Olascoaga J, Prevost J, Aguera-Morales E, Slee M, Csepany T, Turkoglu R, Sidhom Y, Gouider R, Van Wijmeersch B, McCombe P, Macdonell R, Coles A, Malpas CB, Butzkueven H, Vukusic S, Kalincik T; MSBase; OFSEP investigators. Roos I, et al. Among authors: vukusic s. Brain. 2020 Sep 1;143(9):2742-2756. doi: 10.1093/brain/awaa231. Brain. 2020. PMID: 32947619 Free article.
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
Otero-Romero S, Lebrun-Frénay C, Reyes S, Amato MP, Campins M, Farez M, Filippi M, Hacohen Y, Hemmer B, Juuti R, Magyari M, Oreja-Guevara C, Siva A, Vukusic S, Tintoré M. Otero-Romero S, et al. Among authors: vukusic s. Mult Scler. 2023 Jul;29(8):904-925. doi: 10.1177/13524585231168043. Epub 2023 Jun 9. Mult Scler. 2023. PMID: 37293841 Free PMC article. Review.
Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis.
Androdias G, Noroy L, Psimaras D, Birzu C, Pelletier J, Beigneux Y, Branger P, Ciron J, Dananchet Y, Depaz R, Froment Tilikete C, Gignoux L, Grosset-Janin C, Joubert B, Kerschen P, Kwiatkowski A, Lebrun-Frenay C, Maillart E, Maureille A, Nicolas P, Roux T, Marignier R, Vukusic S; as the ICI-SEP group, under the aegis of the Société Francophone de la Sclérose en Plaques (SFSEP). Androdias G, et al. Among authors: vukusic s. Neurol Neuroimmunol Neuroinflamm. 2024 Mar;11(2):e200202. doi: 10.1212/NXI.0000000000200202. Epub 2024 Feb 12. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38346268 Free PMC article.
Aggressive multiple sclerosis (2): Treatment.
Arrambide G, Iacobaeus E, Amato MP, Derfuss T, Vukusic S, Hemmer B, Brundin L, Tintore M; 2018 ECTRIMS Focused Workshop Group. Arrambide G, et al. Among authors: vukusic s. Mult Scler. 2020 Jun 12;26(9):1352458520924595. doi: 10.1177/1352458520924595. Online ahead of print. Mult Scler. 2020. PMID: 32530366 Free PMC article.
280 results